Literature DB >> 15824522

Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists.

Gregory B Diette1, John C Scatarige, Edward F Haponik, Barry Merriman, Elliot K Fishman.   

Abstract

BACKGROUND: High-resolution CT (HRCT) of the lungs has become an essential component to evaluate patients with diffuse lung disease. Little is known, however, about the current practices of pulmonologists caring for patients with these complex conditions, and, in particular, whether HRCT can obviate the need for surgical lung biopsy.
OBJECTIVES: To investigate the practices of pulmonologists concerning the acceptability of a HRCT diagnosis in lieu of lung biopsy in diffuse lung disease.
METHODS: We asked practicing pulmonologists among membership of the American College of Chest Physicians whether HRCT results could replace lung biopsy in 16 diffuse lung diseases. Responses were examined in light of published evidence, practice guidelines, and certain practice parameters.
RESULTS: Two hundred and thirty (52.6%) of 437 eligible physicians responded. Sixty-seven percent (67%) of respondents accepted HRCT diagnosis for idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP) despite their awareness of guidelines recommending histological diagnosis. Most would not accept a radiologic diagnosis for lymphangioleiomyomatosis (LAM; 37%) or eosinophilic granuloma (Langerhans' cell histiocytosis, LCH; 19%), even though CT findings are frequently characteristic. Responses were similar by type of clinical practice and recency of fellowship training. Chest physicians who referred patients for HRCT more frequently were more likely to accept HRCT diagnosis (p=0.008) and those who had higher self-ratings of proficiency in reading HRCT (p = 0.004) were more likely to believe HRCT often suggests specific diagnosis.
CONCLUSIONS: Most US pulmonologists will accept an HRCT diagnosis of IPF/UIP without lung biopsy, but are reluctant to do so for most other diffuse lung conditions including LAM and LCH. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15824522     DOI: 10.1159/000084043

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?

Authors:  Kevin R Flaherty; Adin-Cristian Andrei; Talmadge E King; Ganesh Raghu; Thomas V Colby; Athol Wells; Nadir Bassily; Kevin Brown; Roland du Bois; Andrew Flint; Steven E Gay; Barry H Gross; Ella A Kazerooni; Robert Knapp; Edmund Louvar; David Lynch; Andrew G Nicholson; John Quick; Victor J Thannickal; William D Travis; James Vyskocil; Frazer A Wadenstorer; Jeffrey Wilt; Galen B Toews; Susan Murray; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

2.  Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis?

Authors:  Chiara Romei; Laura Tavanti; Paola Sbragia; Annalisa De Liperi; Laura Carrozzi; Ferruccio Aquilini; Antonio Palla; Fabio Falaschi
Journal:  Radiol Med       Date:  2015-03-06       Impact factor: 3.469

3.  Quantitative computed tomography imaging of interstitial lung diseases.

Authors:  Brian J Bartholmai; Sushravya Raghunath; Ronald A Karwoski; Teng Moua; Srinivasan Rajagopalan; Fabien Maldonado; Paul A Decker; Richard A Robb
Journal:  J Thorac Imaging       Date:  2013-09       Impact factor: 3.000

Review 4.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

5.  Is there a uniform approach to the management of diffuse parenchymal lung disease (DPLD) in the UK? A national benchmarking exercise.

Authors:  Patricia Macedo; Robina K Coker; Martyn R Partridge
Journal:  BMC Pulm Med       Date:  2007-03-13       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.